All In Biotech

Drug Trial Radar · NCT00567411

Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty

Last checked: Nov 19, 2026Latest source record: Dec 5, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

43

Planned (sponsor's estimate)

Start

Aug 2006

Primary completion

Not stated

Study completion Jun 2009

Sponsor

Lead sponsor
Walter Reed Army Medical CenterFederal agency
Sponsor type
Federal agency
First posted
Dec 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the safety and efficacy of two drops used to lower eye pressure when given prior to a glaucoma laser procedure.

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • brimonidine 0.1%Drug

    1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)

  • Apraclonidine 0.5%Drug

    1 drop applied 1 hour prior to SLT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Postoperative IOPTime frame: 1 hour and 1 week post surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Walter Reed Army Medical Center

    Washington D.C., District of Columbia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.